ClinicalTrials.Veeva

Menu

Safety of Imovax Polio in Chinese Infants and Children

Sanofi logo

Sanofi

Status and phase

Completed
Phase 3

Conditions

Poliomyelitis

Treatments

Biological: Inactivated Poliomyelitis vaccine

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

To describe the tolerance in terms of occurrence of serious adverse reactions and severe adverse reactions (injection site and systemic) within eight days after one dose of IMOVAX Polio™ administered in children and infants.

Enrollment

40 patients

Sex

All

Ages

2 to 18 months old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Group 1: Aged 18 months (18-20 months) on the day of inclusion
  • Group 2: Aged 2 months (56-70 days) on the day of inclusion

Exclusion criteria

  • Participation in another clinical trial in the 4 weeks preceding the trial vaccination
  • Planned participation in another clinical trial during the present trial period
  • Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy
  • Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances
  • Chronic illness at a stage that could interfere with trial conduct or completion
  • Blood or blood-derived products received in the past 3 months (for Group 1) or since birth (for Group 2)
  • Any vaccination in the 4 weeks preceding the trial vaccination (except BCG and Hepatitis B [Hep B] for Group 2)
  • Vaccination planned in the 4 weeks following the trial vaccination
  • Group 1: Previous booster vaccination against the poliomyelitis infection with the trial vaccine or with another vaccine.
  • Group 2: Previous vaccination against the poliomyelitis infection with the trial vaccine or with another vaccine.
  • History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically)
  • Clinical or serological evidence of systemic illness including Hepatitis B, C and HIV
  • Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination
  • History of/current seizures
  • Febrile illness (axillary temperature ≥ 37.4°C) or acute illness on the day of inclusion

Trial design

Primary purpose

Prevention

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

40 participants in 2 patient groups

Group 1
Experimental group
Description:
Children at 18 months of age
Treatment:
Biological: Inactivated Poliomyelitis vaccine
Biological: Inactivated Poliomyelitis vaccine
Group 2
Experimental group
Description:
Infants at 2 months of age
Treatment:
Biological: Inactivated Poliomyelitis vaccine
Biological: Inactivated Poliomyelitis vaccine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems